Applications of Boc-D-Tic-OH in Industrial Manufacturing

Boc-D-Tic-OH serves as a specialized protected amino acid derivative used predominantly in the peptide synthesis industry, with applications concentrated in pharmaceutical API development, biomedical peptide research, diagnostic reagent formulation, and veterinary peptide product manufacturing. Our production facility supplies this raw material directly to manufacturers who adhere to stringent quality, regulatory, and process integration benchmarks.

1. Active Pharmaceutical Ingredient (API) Peptide Synthesis

Pharmaceutical companies utilize Boc-D-Tic-OH as a chiral building block in the stepwise synthesis of complex therapeutic peptides, particularly those involving non-standard D-amino acid residues to modulate pharmacological profiles. Integration occurs at the protected amino acid coupling stage, critical for assembling peptide chains resistant to enzymatic degradation, which directly supports the manufacture of synthetic peptide APIs targeting oncology, metabolic, or infectious diseases. Our customers require tight control over configuration and purity to meet drug master file submissions and regulatory review for global markets.

Industry compliance standards

• ICH Q7 GMP Guidelines for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) General Chapter <1045> on Peptide Synthesis
• European Pharmacopoeia (Ph. Eur.) requirements for peptide substances
• EDQM CEP (Certificate of Suitability) framework

Typical usage ratio

• In solution-phase or solid-phase peptide syntheses, Boc-D-Tic-OH input matches precise stoichiometry: 1.0–1.2 equivalents per peptide coupling cycle, subject to resin loading efficiency and desired peptide batch size. Excess is minimized to reduce downstream deprotection waste and purification costs.

Downstream process integration

• Pepide assembly lines introduce the protected amino acid at designated elongation steps via automated synthesizers or manual batch processes, before final deprotection, cleavage from resin, and chromatographic purification stages.

Final product types

• GMP-grade peptide APIs for targeted small-molecule drugs (e.g., receptor antagonists)
• Peptide-based drug candidates for clinical trials
• Reference standards for analytical method validation in regulatory submissions

2. Biomedical Research Peptide Library Synthesis

Research institutes, contract development organizations, and biotechnology R&D centers employ our product in high-throughput synthesis of custom peptide libraries for structure-activity studies, molecular interaction profiling, and biomarker discovery projects. Its configuration as a protected D-amino acid supports the incorporation of conformational constraints, yielding libraries instrumental for screening novel biological functions and therapeutic leads. Product shipment meets strict documentation and batch certification requirements for traceability and reproducibility in international collaborations.

Industry compliance standards

• ISO 9001:2015 Quality Management System (for lab-scale production and supply chain)
• OECD Good Laboratory Practice (GLP) for non-clinical laboratories
• REACH Regulation (EC) No 1907/2006 for research chemicals
• Material Safety Data Sheet (MSDS) availability for all supplied lots

Typical usage ratio

• High-throughput array synthesis protocols recommend Boc-protected residues at 1:1 molar ratios per coupling step; in split-and-mix library formats, use may range from 0.8 to 1.2 equivalents, adjusted for solid support swelling and chain loading needs.

Downstream process integration

• The material enters at each residue addition cycle in automated peptide synthesizers, followed by on-resin deprotection, pool consolidation, and ultrafiltration for purification prior to microplate formatting or immobilization on assay surfaces.

Final product types

• Synthetic peptide libraries for binding interaction assays
• Custom peptides for molecular recognition studies
• Tagged peptides for high-content screening platforms

3. In Vitro Diagnostic (IVD) Reagent Manufacturing

IVD companies source Boc-D-Tic-OH to facilitate synthesis of highly specific peptide antigens and substrates utilized in immunoassays, enzyme panels, or diagnostic probe kits. Controlled use in the assembly of peptides bearing non-standard residues increases the selectivity and specificity of test reagents, essential for reducing background cross-reactivity in serological or enzymatic diagnostics. Our manufacturing and QC processes directly support reagent manufacturers working under global harmonization initiatives for clinical diagnostics.

Industry compliance standards

• ISO 13485:2016 Medical Devices Quality Management
• European Union IVDR (Regulation (EU) 2017/746)
• US FDA 21 CFR Part 820 Quality System Regulation for diagnostics
• CLSI C62-A Guidelines for peptide-based diagnostic reagents

Typical usage ratio

• Chemical synthesis of diagnostic peptides: 0.9–1.1 equivalents per sequence step, fine-tuned to peptide length and required purity for downstream conjugation.

Downstream process integration

• The intermediate is coupled during SPPS cycles prior to selective deprotection, then subjected to HPLC purification before lyophilization and formulation into diagnostic kit components.

Final product types

• Peptide antigens for ELISA kits
• Substrate peptides for enzyme-based IVD kits
• Affinity peptides for lateral flow diagnostic devices

4. Veterinary Peptide Pharmaceutical Manufacturing

Companies specializing in animal health synthesize bioactive peptides, particularly those incorporating D-amino acid building blocks to improve resistance to enzymatic breakdown in veterinary applications. The use of Boc-D-Tic-OH in peptide chain assembly contributes to the extended in vivo action of antiparasitic or reproductive health products. Veterinary pharmaceutical manufacturers must align use of each protected amino acid with feed additive and medication residue constraints in the global supply chain.

Industry compliance standards

• VICH GL GMP Guidance for active substances (animal health)
• World Organisation for Animal Health (WOAH, OIE) safety and residue monitoring frameworks
• US FDA Guidance for Industry #152 on veterinary peptides
• Relevant national pharmacopoeia monographs for peptide-based veterinary APIs

Typical usage ratio

• Peptide bulk synthesis for veterinary APIs typically incorporates Boc-protected residues in equimolar (1:1) coupling ratios; some adaptation based on animal metabolic tolerance group and peptide target length.

Downstream process integration

• The product is added during chain elongation on automated or semi-automated SPPS synthesizers; subsequent deprotection and isolation steps follow to yield the protected intermediate, which is then further processed to active veterinary ingredient form.

Final product types

• Peptide-based veterinary injection concentrate
• Medicated animal feed additives
• Veterinary diagnostic stimulants for herd health management